pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
PFIZER · news · pharmadog
← back to PFIZER
News mentioning PFIZER
194
stories
Jun 8, 26
STAT+: UnitedHealthcare’s lactation billing feud, and fake strokes
stat
Jun 8, 26
GSK inks multi-target pact with Engitix; Sangamo considers strategic options
endpoints
Jun 8, 26
STAT+: Novo underwhelmed by drug it once fought Pfizer for
stat
Jun 8, 26
STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more
stat
Jun 8, 26
STAT+: J&J spends $1 billion to enter KRAS race for cancer treatments
stat
Jun 8, 26
Major readouts from the annual diabetes conference
stat
Jun 8, 26
STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate
stat
Jun 8, 26
Opinion: $2 million gene therapy cures require a financing model
stat
Jun 7, 26
STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
stat
Jun 6, 26
STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug
stat
Jun 6, 26
#ADA26: Pfizer's monthly shot shows effect on obesity, diabetes
endpoints
Jun 6, 26
STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential
stat
Jun 5, 26
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
biopharma dive
Jun 4, 26
Otsuka showcases kidney drug data; Pfizer cuts an AI deal
biopharma dive
Jun 4, 26
STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more
stat
Jun 4, 26
STAT+: Does Revolution Medicines’ pancreatic cancer drug have even greater potential?
stat
Jun 3, 26
House bill aims to crack down on China biotech deals
biopharma dive
Jun 3, 26
STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more
stat
Jun 2, 26
Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
biopharma dive
Jun 2, 26
Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug
biopharma dive
Jun 2, 26
STAT+: Pharmalittle: We’re reading about a Lilly threat to 340B hospitals, Ebola vaccine funding, and more
stat
Jun 1, 26
STAT+: Eli Lilly warns hospitals to submit claims data in the next five days or lose their 340B drug discounts
stat
Jun 1, 26
STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
stat
Jun 1, 26
2026 Orphan Drugs Report: A safe(r) passage amid stormy waters?
biopharma dive
May 31, 26
STAT+: A standing ovation for RevMed, and caution for Akeso
stat
May 31, 26
Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
stat
May 31, 26
STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
stat
May 31, 26
STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
stat
May 31, 26
STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds
stat
May 30, 26
STAT+: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA
stat
← prev
page 5 of 7
next →
